



		United States Patent and Trademark Office		DEWIPAT File No. 30.037.10.US
Form 1401A (5-04) (Modified)		Information Disclosure Citation		Sheet 1 of 2
Application No.	10/698,894	Attorney Docket	ARC3244R1	
Filing Date	10/31/2003	Customer No.	27777	
Applicant	Liang C. Dong	Confirmation No.	2950	
Examiner		Art Unit	1615	
Title	Formulation and Dosage Form Providing Increased Bioavailability of Hydrophobic Drugs			

U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No.	Document Number Number-Kind Code	Publication Date mm-dd-yyyy	Applicant/Patentee
MDX	A1	US-2002119198-A1	08-29-2002	GAO, Ping
	A2	US-2003133974-A1	07-17-2003	CURATOLO, William
	A3	US-2003232078-A1	12-18-2003	DONG, Liang
	A4	US-3845770	05-11-1974	THEEUWES, Felix
	A5	US-3916899	04-11-1975	THEEUWES, Felix
	A6	US-4077407	03-07-1978	THEEUWES, Felix
	A7	US-4200098	04-29-1980	AYER, Atul D.
	A8	US-4627850	12-09-1986	DETERS, Joseph C.
	A9	US-4627851	12-09-1986	WONG, Patrick S.L.
	A10	US-4915949	04-10-1990	WONG, Patrick S.L.
	A11	US-4931285	06-05-1990	EDGREN, David E.
	A12	US-5006346	04-09-1991	EDGREN, David E.
	A13	US-5024842	06-18-1991	EDGREN, David E.
	A14	US-5126142	06-30-1992	AYER, Atul D.
	A15	US-5160743	11-03-1992	EDGREN, David E.
	A16	US-5190765	03-02-1993	JAO, Frank
	A17	US-5252338	10-12-1993	JAO, Frank
	A18	US-5324280	06-28-1994	WONG, Patrick S.L.
	A19	US-5413572	05-09-1995	WONG, Patrick S.L.
	A20	US-5578642	11-26-1996	SHALKA, Barry A.
	A21	US-5614578	03-25-1997	DONG, Liang
	A22	US-5620705	04-15-1997	DONG, Liang
	A23	US-5633011	05-27-1997	DONG, Liang
	A24	US-5660861	08-26-1997	JAO, Frank
	A25	US-5965160	10-12-1999	BENITA, Simon
	A26	US-6057289	05-02-2000	MULYE, Nirmal
	A27	US-6174547	01-16-2001	DONG, Liang
	A28	US-6183466	02-06-2001	WONG, Patrick S.L.
	A29	US-6221391	04-24-2001	ROUFFER, Mark T.
	A30	US-6245357	06-12-2001	EDGREN, David E.
MDX	A31	US-6284268	09-04-2001	MISHRA, Awadhesh

EXAMINER: Michael J. Young

DATE CONSIDERED: 1/4/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		United States Patent and Trademark Office	DEWIPAT File No. 30.037.10.US	
Form PTO-1449 (Modified)		Information Disclosure Citation		Sheet 2 of 2
Application No.		10/698,894	Attorney Docket	ARC3244R1
Filing Date		10/31/2003	Customer No.	27777
Applicant		Liang C. Dong	Confirmation No.	2950
Examiner			Art Unit	1615
Title		Formulation and Dosage Form Providing Increased Bioavailability of Hydrophobic Drugs		

U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No.	Document Number Number-Kind Code	Publication Date mm-dd-yyyy	Applicant/Patentee
WHD	A32	US-6342249	01-29-2002	WONG, Patrick S.L.
	A33	US-6419952	07-16-2002	WONG, Patrick S.L.
	A34	US-6436430	08-20-2002	MULYE, Nirmal
MLY	A35	US-6551613-B1	04-22-2003	DONG, Liang


FOREIGN PATENT DOCUMENTS				
Examiner Initials*	Cite No.	Document Number Number-Kind Code	Publication Date mm-dd-yyyy	Applicant/Patentee
MLY	A36	WO-02/22158-A1	03-21-2002	RPG Life Sciences Limited

NON-PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (In CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
MLY	A37	PCT International Search Report Dated 04/06/2004		

EXAMINER: M. Liang

DATE CONSIDERED: 1/4/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



	United States Patent and Trademark Office	DEWIPAT File No. 30.037.10.US	
Form PTO-1449 (Modified)	Information Disclosure Citation		
	Sheet 1 of 1		
Application No.	10/698,894	Attorney Docket	ARC3244R1
Filed (yyyy-mm-dd)	2003-10-31	Customer No.	27777
Applicant	Liang C. Dong	Confirmation No.	2950
Examiner		Art Unit	1615
Title	Formulation and Dosage Form Providing Increased Bioavailability of Hydrophobic Drugs		

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number Number-Kind Code	Publication Date yyyy-mm-dd	Applicant/Patentee	T
MPS	B1	WO 99/01113	1999-01-14	Pfizer Products Inc.	
	B2	WO 00/13674	2000-03-16	Alza Corporation	
	B3	WO 02/07712	2002-01-31	Pharmacia & Upjohn Company	
X	B4	WO 03/053400	2003-07-03	Alza Corporation	

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T

EXAMINER: Michael J. W.

DATE CONSIDERED: 1/4/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.